Total Debt (Carrying Amount)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Debt item | Description | The company |
---|---|---|
Total long-term debt and finance lease liabilities (carrying amount) | Sum of the carrying values as of the balance sheet date of all debt plus capital lease obligations. | Regeneron Pharmaceuticals Inc. total debt increased from 2021 to 2022 and from 2022 to 2023. |
Total Debt (Fair Value)
Dec 31, 2023 | |
---|---|
Selected Financial Data (US$ in thousands) | |
Long-term debt | 1,528,000) |
Finance lease liabilities | 720,000) |
Total long-term debt and finance lease liabilities (fair value) | 2,248,000) |
Financial Ratio | |
Debt, fair value to carrying amount ratio | 0.83 |
Based on: 10-K (reporting date: 2023-12-31).
Weighted-average Interest Rate on Debt
Weighted-average interest rate on debt and finance lease liabilities: 2.92%
Interest rate | Debt amount1 | Interest rate × Debt amount | Weighted-average interest rate2 |
---|---|---|---|
1.75% | 1,242,200) | 21,739) | |
2.80% | 740,700) | 20,740) | |
5.08% | 720,000) | 36,576) | |
Total | 2,702,900) | 79,054) | |
2.92% |
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in thousands
2 Weighted-average interest rate = 100 × 79,054 ÷ 2,702,900 = 2.92%